Literature DB >> 18072114

Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early?

Jason B Hack1, Robert S Hoffmann, Lewis S Nelson.   

Abstract

INTRODUCTION: While most patients with alcohol withdrawal (AW) respond to standard treatment that includes doses of benzodiazepines, nutrition and good supportive care (non resistant alcohol withdrawal-NRAW), a subgroup may resist therapy (resistant alcohol withdrawal-RAW). This study describes a distinct group of AW patients, their sedative requirements, and hospital courses.
METHODS: Over a period of 6 months, AW patients requiring 50 mg diazepam IV in the first hour were followed. We recorded admission indices and diazepam doses with vital signs at 1, 2, 3, 6, 12, and 24 hours. Patients were considered to have RAW if they required additional sedatives for control of symptoms and/or were having persistent abnormal vital signs despite the physicians' choices of therapy.
RESULTS: Nineteen patients were enrolled; all had similar admission indices. While the 4 NRAW had normal vital signs within 3 hours, all 15 RAW patients had abnormal vital signs; 15 RAW patients required escalating diazepam doses--14 required barbiturates, 7 were intubated, and 5 had hypotension. Comparing groups: interval and total diazepam doses were not different at 1,2, and 3 hours; interval doses at 6 and 12 hours, and total doses at 6, 12, and 24 hours were significantly different.
CONCLUSIONS: RAW patients require large doses of benzodiazepine administration, additional sedatives, and undergo complicated hospitalizations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18072114      PMCID: PMC3550056          DOI: 10.1007/bf03161171

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  10 in total

1.  An experimental study of the etiology of rum fits and delirium tremens.

Authors:  H ISBELL; H F FRASER; A WIKLER; R E BELLEVILLE; A J EISENMAN
Journal:  Q J Stud Alcohol       Date:  1955-03

2.  Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients.

Authors:  T M Jaeger; R H Lohr; V S Pankratz
Journal:  Mayo Clin Proc       Date:  2001-07       Impact factor: 7.616

3.  Alcohol withdrawal reactions in mouse strains selectively bred for long or short sleep times.

Authors:  D B Goldstein; R Kakihana
Journal:  Life Sci       Date:  1975-09-15       Impact factor: 5.037

4.  Loading dose diazepam therapy for alcohol withdrawal state.

Authors:  S Manikant; B M Tripathi; B S Chavan
Journal:  Indian J Med Res       Date:  1993-08       Impact factor: 2.375

5.  Effects of diazepam on ethanol withdrawal.

Authors:  L M Aaronson; D J Hinman; M Okamoto
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

6.  Refractory delirium tremens treated with propofol: a case series.

Authors:  C McCowan; P Marik
Journal:  Crit Care Med       Date:  2000-06       Impact factor: 7.598

7.  Assessment of diazepam loading dose therapy of delirium tremens.

Authors:  D Wasilewski; H Matsumoto; E Kur; A Dziklińska; E Woźny; K Stencka; M Skalski; P Chaba; W Szelenberger
Journal:  Alcohol Alcohol       Date:  1996-05       Impact factor: 2.826

8.  Admission alcohol level: a predictor of the course of alcohol withdrawal.

Authors:  D C Vinson; M Menezes
Journal:  J Fam Pract       Date:  1991-08       Impact factor: 0.493

9.  Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial.

Authors:  R Saitz; M F Mayo-Smith; M S Roberts; H A Redmond; D R Bernard; D R Calkins
Journal:  JAMA       Date:  1994-08-17       Impact factor: 56.272

10.  Ethanol withdrawal-induced up-regulation of the alpha2 subunit of the GABAA receptor and its prevention by diazepam or gamma-hydroxybutyric acid.

Authors:  Paolo Follesa; Francesca Biggio; Luisa Mancuso; Stefano Cabras; Stefania Caria; Giorgio Gorini; Annalisa Manca; Alessandro Orru; Giovanni Biggio
Journal:  Brain Res Mol Brain Res       Date:  2004-01-05
  10 in total
  15 in total

1.  A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens.

Authors:  Jeffrey A Gold; Binaya Rimal; Anna Nolan; Lewis S Nelson
Journal:  Crit Care Med       Date:  2007-03       Impact factor: 7.598

2.  Racial variations in the incidence of severe alcohol withdrawal.

Authors:  Gar Ming Chan; Robert S Hoffman; Jeffrey A Gold; Paula J Whiteman; Lewis R Goldfrank; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2009-03

3.  Alcohol withdrawal and flumazenil: not for the faint of heart.

Authors:  Lewis S Nelson
Journal:  J Med Toxicol       Date:  2014-06

4.  Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review.

Authors:  Drayton A Hammond; Jordan M Rowe; Adrian Wong; Tessa L Wiley; Kristen C Lee; Sandra L Kane-Gill
Journal:  Hosp Pharm       Date:  2017-07-17

5.  Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.

Authors:  Manu Jose; Jayanthi Mathaiyan; Shivanand Kattimani; Surendiran Adithan; Adithan Chandrasekaran
Journal:  Eur J Clin Pharmacol       Date:  2016-04-20       Impact factor: 2.953

Review 6.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 7.  Intermittent hypoxia training: Powerful, non-invasive cerebroprotection against ethanol withdrawal excitotoxicity.

Authors:  Marianna E Jung; Robert T Mallet
Journal:  Respir Physiol Neurobiol       Date:  2017-08-12       Impact factor: 1.931

8.  Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome.

Authors:  Valentin Yurievich Skryabin; Mikhail Zastrozhin; Marco Torrado; Elena Grishina; Kristina Ryzhikova; Valery Shipitsyn; Tatiana Galaktionova; Alexander Sorokin; Evgeny Bryun; Dmitry Sychev
Journal:  Hosp Pharm       Date:  2020-06-02

9.  Characterization of the GHB Withdrawal Syndrome.

Authors:  Casper J H Wolf; Harmen Beurmanjer; Boukje A G Dijkstra; Alexander C Geerlings; Marcia Spoelder; Judith R Homberg; Arnt F A Schellekens
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

Review 10.  Pellagrous encephalopathy presenting as alcohol withdrawal delirium: a case series and literature review.

Authors:  Mark A Oldham; Ana Ivkovic
Journal:  Addict Sci Clin Pract       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.